Evidence map›Paper›PMID 38775116›Full record

ReviewMolecular oncology2025

Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells.

Doryan Masmoudi, Jérome Vialaret, Christophe Hirtz, Catherine Alix-Panabières

Abstract readReview
In one paragraph

Review in Molecular oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Circulating Tumor Cells: Emerging Frontiers in Cancer Technology.Expert reviews in molecular medicine · 2026
    Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Doryan MasmoudiLaboratory of Rare Circulating Human Cells, University Medical Center of Montpellier, France.ORCID https://orcid.org/0009-0003-3298-0904
Jérome VialaretUniversity of Montpellier, IRMB-PPC, INM, CHU Montpellier, INSERM CNRS, France.
Christophe HirtzUniversity of Montpellier, IRMB-PPC, INM, CHU Montpellier, INSERM CNRS, France.
Catherine Alix-PanabièresLaboratory of Rare Circulating Human Cells, University Medical Center of Montpellier, France.ORCID https://orcid.org/0000-0002-6401-2903

Funding

Fondation ARC pour la Recherche sur le CancerFonds de dotation AFER pour la recherche médicale
6 · The paper itself

Abstract

Circulating tumor cells (CTCs) are cancer cells that detach from the original site and reach the bloodstream. The most aggressive CTCs survive various immune system attacks and initiate metastasis formation. Importantly, CTCs are not specifically targeted by the current immunotherapies due to the limited knowledge on specific targets. Proteomic profiling can be a powerful tool for understanding some of the immune evasion mechanisms used by cancer cells and particularly CTCs. These mechanisms are generally linked to the expression of specific surface proteins/peptides (i.e. the surfaceome). The study of the peptides that bind to class I molecules of the major histocompatibility complex (MHC-I) and of the various glycoproteins expressed on CTC surface may open a completely new avenue for the discovery of novel mechanisms of immune evasion. In this review, we discuss how immunopeptidomic and glycoproteomic studies of CTCs that interact with immune cells could help to better understand how metastasis-initiator CTCs escape the host immune response. We also describe how immunopeptidomic and glycoproteomic studies are carried out.

Indexed as

Immune EvasionNeoplasmsNeoplastic Cells, CirculatingTumor EscapeAnimalsHumansProteomicscancercirculating tumor cellsglycoproteomicsimmunopeptidomicsproteomics

Identifiers

PMID38775116
PMCPMC12234394

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.